ActiveMSers Forums  

Go Back   ActiveMSers Forums > Forums > Dave's SCT Journey

Thread Tools Display Modes
Old 03-17-2016, 01:48 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 4,070
Default Russian study: 5% risk of death, 45% progression free after 5 yrs

Important notes from this Russian study: 5% death rate and 45% of those transplanted were progression free after 5 years. Decent results, but hardly a slam dunk in this case. Fine tuning patient selection should help those numbers. - D

Makarov SV, Rossiev VA, Mishchenko OV, Kozlov VA, Semagina OV, Aleksandrova IY, Grishina GV, Minaev YL.

The role and place of high-dose immunosuppressive therapy and autologous transplantation of hematopoietic stem cells for autoimmune diseases

Ter Arkh. 2016;88(1):53-59.

AIM: To determine the possible boundaries of high-dose immunosuppressive therapy and autologous haematopoietic stem cell transplantation (HDIT-autoHSCT) for autoimmune diseases (AUDs), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS).

MATERIAL AND METHODS: A long-term trial was conducted at one center to evaluate the efficiency and safety of HDIT-autoHSCT in patients with AUDs. The previous standard therapy was noted to be resistant or lowly effective. The age of 10 patients with systemic connective tissue diseases was 27.62.8 years; the pre-HDIT-autoHSCT disease duration was 5.91.3 years; the median posttransplantation follow-up was 39.3 months. The age of 49 patients with MS reached 34.91.33 years; the pretransplantation disease duration was 8.40.69 years; the median post-HDIT-autoHSCT follow-up was 42 months. The efficiency of transplantation was evaluated on the basis of clinical findings, by using scales, laboratory tests, and magnetic resonance imaging. Pretransplantation conditioning was carried out according to the protocols: a) BEAM + antilymphocyte globulin (ALG); b) fludarabine + melphalan + ALG. No fatal outcomes due to a transplant procedure were observed.

RESULTS: Overall 5-year survival after transplantation was 80% for systemic connective tissue diseases and 95% for MS; 5-year progression-free survival rates were 30% in the RA and SLE groups and 45% in the MS group. HDIT-autoHSCT turned out safe and reduced the activity of the process and further disease progression for a long period of time, as confirmed by regression of clinical symptoms and/or status stabilization in 9 patients with SLE or RA and in all patients with MS.

CONCLUSION: The favorable factors associated with the results of transplantation are age younger than 35 years in collagenoses with their short-term duration and moderate signs; age younger than 40 years in MS with a disease duration of less than 10 years and expanded disability status scale scores of not more than 6.5. Of importance are functional system scores, duration of first remission, and an index of disease progression in different types of MS.
Dave Bexfield
Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

All times are GMT -4. The time now is 02:38 PM.

Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.